Otonomy

Otonomy ROCE

Delisted

The Return on Capital Employed (ROCE) of Otonomy (OTIC) as of Nov 10, 2026 is -90.38 %. In the previous year, Return on Capital Employed (ROCE) was -65.14 % — a change of 38.74% (lower).

ROCE

-90.38 %

YoY

38.74%

Last updated:

In 2021, Otonomy's return on capital employed (ROCE) was -90.38 %, a 38.74% increase from the -65.14 % ROCE in the previous year.

The Otonomy ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2014
-25.81 USD
Jan 1, 2015
-34.15 USD
Jan 1, 2016
-57.85 USD
Jan 1, 2017
-77.92 USD
Jan 1, 2018
-65.31 USD
Jan 1, 2019
-111.47 USD
Jan 1, 2020
-65.14 USD
Jan 1, 2021
-90.38 USD
The Otonomy ROCE history
YEARROCEYoY
-90.38 %+38.74%
-65.14 %-41.56%
-111.47 %+70.68%
-65.31 %-16.19%
-77.92 %+34.69%
-57.85 %+69.41%
-34.15 %+32.32%
-25.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Otonomy Stock analysis

What does Otonomy do? Otonomy Inc is a biopharmaceutical company focused on developing innovative therapies for inner ear disorders. The company was founded in 2008 in San Diego, California and has since made significant advancements to bring its products to market. Otonomy's business model is based on identifying unmet medical needs in the field of otolaryngology. The company develops and markets FDA-approved ear medications that are designed in new and innovative ways to improve the treatment of hearing and balance disorders. The different divisions of Otonomy include clinical research, product development, manufacturing, and distribution. The company has an experienced team of scientists, engineers, clinical researchers, and managers who work closely together to develop and bring Otonomy's pipeline of drug candidates to market. The company has launched a number of products targeting the needs of patients with inner ear disorders. For example, the medication Otiprio was developed to treat otitis media, an inflammation of the middle ear. Otiprio is delivered directly into the ear during a minor surgery, where it quickly acts to eliminate the inflammation. Another one of Otonomy's products is Otividex, a medication developed to treat patients with Meniere's disease. This condition is a rare inner ear disorder that causes dizziness, tinnitus, and hearing loss. Otividex is also delivered directly into the ear and has shown to alleviate the dizziness symptoms and improve hearing. In recent years, Otonomy has also developed a new technology called OTO-413, which aims to improve hearing by regenerating damaged hair cells in the inner ear. The company has successfully conducted clinical trials with OTO-413 and plans to further explore and develop the technology. Otonomy has also formed partnerships with other companies and organizations in recent years to further develop its technologies and bring new products to market. For example, the company has entered into a collaboration agreement with Merck to develop new therapies for inner ear disorders. Otonomy also collaborates with a number of academic institutions and research facilities to further explore and develop the potential of its technologies. Overall, Otonomy Inc is an innovative and dynamic company dedicated to developing new therapies for inner ear disorders. With a strong pipeline of drug candidates and a dedicated group of scientists and researchers, the company is well positioned to make significant advancements in the treatment of hearing and balance disorders in the coming years. Otonomy is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Otonomy's Return on Capital Employed (ROCE)

Otonomy's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Otonomy's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Otonomy's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Otonomy’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Otonomy stock

Return on Capital Employed (ROCE) of Otonomy is -90.38 % in 2021.

Return on Capital Employed (ROCE) of Otonomy changed from -65.14 % to -90.38 %, representing a 38.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Otonomy since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Otonomy with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Otonomy

All Key Metrics — Otonomy